E
enGene Holdings Inc. (ENGN)
NCM – Real Time Price. Currency in USD
6.37
-0.59 (-8.48%)
At close: Mar 27, 2026, 4:00 PM EDT
6.45
+0.08 (1.26%)
After-hours: Mar 27, 2026, 6:59 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
6.37
-0.59 (-8.48%)
At close: Mar 27, 2026, 4:00 PM EDT
6.45
+0.08 (1.26%)
After-hours: Mar 27, 2026, 6:59 PM EDT
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
| Name | Position |
|---|---|
| Dr. Alexander Nichols Ph.D. | Chief Strategy & Operations Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Hussein Sweiti M.D., M.Sc. | Chief Medical Officer and Head of Research & Development |
| Mr. David Ryan Daws | CFO & Head of Business Development |
| Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary |
| Mr. Matthew Boyd | Chief Regulatory Officer |
| Mr. Ronald H. W. Cooper | President, CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-09 | S-8 | engn-20260309.htm |
| 2026-01-21 | 8-K | engn-20260120.htm |
| 2025-12-22 | 8-K | engn-20251222.htm |
| 2025-11-14 | 8-K | d876714d8k.htm |
| 2025-10-02 | 8-K | engn-20251002.htm |
| 2025-09-30 | 8-K | engn-20250930.htm |
| 2025-09-11 | 10-Q | engn-20250731.htm |
| 2025-09-03 | 8-K | engn-20250903.htm |
| 2025-07-08 | 8-K | a8k.htm |
| 2025-06-12 | 10-Q | engn-20250430.htm |
| Ms. Jill Buck |
| Chief Development Officer |
| Ms. Joan Connolly | Chief Technology Officer |
| Ms. Tara Place M.B.A. | Senior VP of Human Resources |